MSFT Research Update — September 16, 2026
Updated Thesis
Microsoft is a global infrastructure-software platform spanning Azure, Microsoft 365, security, Dynamics, Windows, GitHub and AI copilots, with high business quality supported by enterprise distribution, explicitly cited switching costs, a $678 billion commercial RPO balance, 67.9% TTM gross margin, 46.8% TTM operating margin, 40.3% TTM net margin and 33.2% ROE. Revenue grew 17.7% and earnings grew 31.3% year over year in the most recent quarter, while FY2026 Q4 Azure and other cloud-services growth was 43%. At $497.12, the shares trade at 27.61x trailing earnings, 11.12x sales, 55.13x free cash flow and 18.31x EV/EBITDA; the historical-multiple regime classifies valuation as fair, but the $702.35 blended fair-value estimate implies 41.3% upside, making the shares undervalued versus blended fair value.
The investment grade as of this refresh is A — high business quality. High-tier business, undervalued-tier valuation, with 41.3% upside to $702.35 fair value and a near-term FY2027 Q1 Azure execution catalyst.
Key Metrics at a Glance
- Revenue growth: +17.7% year over year
- Net margin: 40.3%
- Fair value upside: +41.3% to our estimate of $702
Current price: $497.12
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Microsoft Corporation remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full MSFT research →](/stocks/MSFT)